HDAC9 and breast cancer: Within the first hour of incubating an estrogen receptor alpha-positive (ER+) breast cancer cell line, MCF7, in 50 nM of a potent pan-HDAC inhibitor, LBH589, we observed a marked initial accumulation of acetylated PPARγ, despite overall levels of FLAG-tagged PPARγ remaining unchanged (Fig. 2A).